摘要
恶性肿瘤的治疗已进入"精准治疗"时代,抗肿瘤血管生成的靶向治疗是近年非常热门的研究方向,而肿瘤免疫逃逸是导致肿瘤治疗效果不理想的重要原因之一。抗血管生成治疗不仅能够抑制血管生成,使肿瘤退缩,并且能够减少肿瘤微环境中免疫抑制性细胞数量,提高肿瘤浸润淋巴细胞(tumor-infiltrating lymphocyte,TIL)、细胞毒性淋巴细胞(cytotoxic lymphocyte,CTL)等的数量,从而克服肿瘤免疫逃逸。本研究对抗血管生成药物通过改善肿瘤微环境,增强机体抗肿瘤免疫功能进行综述。
Malignant tumor therapy has entered a new era of "precise treatment." Nowadays, targeted anti- angiogenic agents have become a popular research topic that continues to attract increasing interest. Tumor immune escape plays an indispensable role in therapeutic resistance. Anti-angiogenic therapies not only prevent the tumor angiogenesis and suppress tumor growth but also neutralize tumor escape from a host's immune system by reducing the immunosuppressive cells and increasing the number of tumor-infiltrating lymphocyte(TIL) and cytotoxic lymphocte(CTL). This paper aims to review the mechanism underlying the manner by which anti-angiogenesis enhances immunity by influencing tumor microenvironment.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2016年第9期400-403,共4页
Chinese Journal of Clinical Oncology
关键词
抗血管生成
肿瘤免疫逃逸
肿瘤微环境
anti-angiogenesis
tumor immune escape
tumor microenvironment